Comparison of immunohistochemistry, four in situ hybridization methods and quantitative polymerase chain reaction for the molecular diagnosis of HER2 status in gastric cancer: A study of 55 cases

Staněk,Libor; Rozkoš,Tomáš; Laco,Jan; Ryška,Aleš; Petruželka,Luboš; Důra,Miroslav; Dundr,Pavel

doi:10.3892/mmr.2014.2530

Comparison of immunohistochemistry, four in situ hybridization methods and quantitative polymerase chain reaction for the molecular diagnosis of HER2 status in gastric cancer: A study of 55 cases

Authors:
- Libor Staněk
- Tomáš Rozkoš
- Jan Laco
- Aleš Ryška
- Luboš Petruželka
- Miroslav Důra
- Pavel Dundr
View Affiliations

Affiliations: Department of Pathology, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, CZ-128 00 Prague 2, Czech Republic, The Fingerland Department of Pathology, Faculty of Medicine, Charles University in Prague and University Hospital in Hradec Kralove, CZ-500 05 Hradec Králové, Czech Republic, Department of Oncology, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, CZ-128 00 Prague 2, Czech Republic, First Faculty of Medicine, Charles University in Prague, CZ-128 00 Prague 2, Czech Republic
Published online on: September 2, 2014 https://doi.org/10.3892/mmr.2014.2530
Pages: 2669-2674

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

In the current study, the sensitivity and specificity of methods of HER2 status detection were studied in 55 patients presenting with gastric/gastroesophageal junction carcinoma (30 intestinal and 25 diffuse), in small biopsy (endoscopy; n=33) and resection specimens (n=22). The primary objective of the present study was to compare various methods for the assessment of HER2 status, with regards to the sensitivity and specificity of each method, as well as their concordance. In all cases, the status of HER2 was determined using immunohistochemistry (IHC), fluorescence in situ hybridization (FISH), silver in situ hybridization (SISH), and quantitative polymerase chain reaction (qPCR). The concordance rate between IHC and ISH was 100% for IHC 0 and 3+. The concordance rate for IHC 1+ was 100% between IHC and SISH, and 92.9% between IHC and FISH. The concordance rate among different FISH methods was 100%, between FISH and SISH it was 96.2%, and between qPCR and ISH methods it was 88.5%. Thus, the results demonstrate that different in situ hybridization methods are comparable and that none were superior. Furthermore, the IHC and FISH methods were found to be comparable and the concordance rate was particularly good. qPCR analysis correlated well with the other methods and appears to be a possible alternative tool for detection of the HER2 status. However, the concordance rate of qPCR with other methods was identified to be lower in the diffuse carcinoma group of endoscopy biopsy specimens; therefore investigation of further cases is required.

View Figures

View References

1	Gravalos C and Jimeno A: HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol. 19:1523–1529. 2008. View Article : Google Scholar : PubMed/NCBI
2	Hofmann M, Stoss O, Shi D, et al: Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology. 52:797–805. 2008. View Article : Google Scholar : PubMed/NCBI
3	Pala EE, Bayol U, Ozguzer A and Akman O: HER2 status in gastric cancer: a comparison of two novel in situ hybridization methods (IQ FISH and dual color SISH) and two immunohistochemistry methods (A0485 and HercepTest™). Pathol Res Pract. 209:548–554. 2013.PubMed/NCBI
4	Watson S, Validire P, Cervera P, et al: Combined HER2 analysis of biopsies and surgical specimens to optimize detection of trastuzumab-eligible patients in eso-gastric adenocarcinoma: a GERCOR study. Ann Oncol. 24:3035–3039. 2013. View Article : Google Scholar
5	Bang YJ: Advances in the management of HER2-positive advanced gastric and gastroesophageal junction cancer. J Clin Gastroenterol. 46:637–648. 2012. View Article : Google Scholar : PubMed/NCBI
6	Bang YJ, Van Cutsem E, Feyereislova A, et al: ToGA Trial Investigators: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 376:687–697. 2010. View Article : Google Scholar
7	Daum O, Skálová A, Rozkos T and Laco J: Predictive diagnosis of HER2 in gastric adenocarcinoma. Cesk Patol. 47:160–163. 2011.(In Czech).
8	Ooi A, Kobayashi M, Mai M and Nakanishi I: Amplification of c-erbB-2 in gastric cancer: detection in formalin-fixed, paraffin-embedded tissue by fluorescence in situ hybridization. Lab Invest. 78:345–351. 1998.PubMed/NCBI
9	Man YG, Moinfar F, Bratthauer GL, et al: An improved method for DNA extraction from paraffin sections. Pathol Res Pract. 197:635–642. 2001. View Article : Google Scholar : PubMed/NCBI
10	Jacquemier J, Spyratos F, Esterni B, et al: SISH/CISH or qPCR as alternative techniques to FISH for determination of HER2 amplification status on breast tumors core needle biopsies: a multicenter experience based on 840 cases. BMC Cancer. 13:3512013. View Article : Google Scholar
11	Fock KM: Review article: the epidemiology and prevention of gastric cancer. Aliment Pharmacol Ther. 40:250–260. 2014. View Article : Google Scholar : PubMed/NCBI
12	Sehdev A and Catenacci DV: Gastroesophageal cancer: focus on epidemiology, classification, and staging. Discov Med. 16:103–111. 2013.PubMed/NCBI
13	Brien TP, Depowski PL, Sheehan CE, Ross JS and McKenna BJ: Prognostic factors in gastric cancer. Mod Pathol. 11:870–877. 1998.PubMed/NCBI
14	Fox SB, Kumarasinghe MP, Armes JE, et al: Gastric HER2 Testing Study (GaTHER): an evaluation of gastric/gastroesophageal junction cancer testing accuracy in Australia. Am J Surg Pathol. 36:577–582. 2012. View Article : Google Scholar : PubMed/NCBI
15	Hirschmann A, Lamb TA, Marchal G, Padilla M and Diebold J: Simultaneous analysis of HER2 gene and protein on a single slide facilitates HER2 testing of breast and gastric carcinomas. Am J Clin Pathol. 138:837–844. 2012. View Article : Google Scholar
16	Cho EY, Srivastava A, Park K, et al: Comparison of four immunohistochemical tests and FISH for measuring HER2 expression in gastric carcinomas. Pathology. 44:216–220. 2012. View Article : Google Scholar : PubMed/NCBI
17	Kiyose S, Igarashi H, Nagura K, et al: Chromogenic in situ hybridization (CISH) to detect HER2 gene amplification in breast and gastric cancer: comparison with immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH). Pathol Int. 62:728–734. 2012.
18	Lee S, de Boer WB, Fermoyle S, Platten M and Kumarasinghe MP: Human epidermal growth factor receptor 2 testing in gastric carcinoma: issues related to heterogeneity in biopsies and resections. Histopathology. 59:832–840. 2011. View Article : Google Scholar : PubMed/NCBI
19	Takehana T, Kunitomo K, Kono K, et al: Status of c-erbB-2 in gastric adenocarcinoma: a comparative study of immunohistochemistry, fluorescence in situ hybridization and enzyme-linked immuno-sorbent assay. Int J Cancer. 98:833–837. 2002. View Article : Google Scholar : PubMed/NCBI
20	Yano T, Doi T, Ohtsu A, et al: Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer. Oncol Rep. 15:65–71. 2006.PubMed/NCBI
21	Grin A, Brezden-Masley C, Bauer S and Streutker CJ: HER2 in situ hybridization in gastric and gastroesophageal adenocarcinoma: comparison of automated dual ISH to FISH. Appl Immunohistochem Mol Morphol. 21:561–566. 2013. View Article : Google Scholar : PubMed/NCBI
22	Yan B, Yau EX, Choo SN, et al: Dual-colour HER2/chromosome 17 chromogenic in situ hybridisation assay enables accurate assessment of HER2 genomic status in gastric cancer and has potential utility in HER2 testing of biopsy samples. J Clin Pathol. 64:880–883. 2011. View Article : Google Scholar
23	Marx AH, Tharun L, Muth J, et al: HER-2 amplification is highly homogenous in gastric cancer. Hum Pathol. 40:769–777. 2009. View Article : Google Scholar : PubMed/NCBI
24	García-García E, Gómez-Martin C, Angulo B, et al: Hybridization for human epidermal growth factor receptor 2 testing in gastric carcinoma: a comparison of fluorescence in-situ hybridization with a novel fully automated dual-colour silver in-situ hybridization method. Histopathology. 59:8–17. 2011.PubMed/NCBI
25	Kim MA, Jung EJ, Lee HS, et al: Evaluation of HER-2 gene status in gastric carcinoma using immunohistochemistry, fluorescence in situ hybridization, and real-time quantitative polymerase chain reaction. Hum pathol. 38:1386–1393. 2007.
26	Tvrdík D, Staněk L, Skálová H, Dundr P, Velenská Z and Povysil C: Comparison of the IHC, FISH, SISH and qPCR methods for the molecular diagnosis of breast cancer. Mol Med Rep. 6:439–443. 2012.PubMed/NCBI